Phase 2 Clinical Trial Examines the Efficacy of a Novel Psychedelic for the Treatment of Postpartum Depression
Individuals with postpartum depression are being recruited for a clinical trial of a novel psychedelic compound, RE104.
New Research Study at the CWMH: A Novel Treatment for Menopausal Depression
The transition to menopause, or perimenopause, represents the passage from reproductive to non-reproductive life. During the perimenopause, women experience irregular menstrual cycles, which reflect the large fluctuations in ovarian hormone [...]
Brexanolone: A New Drug for Postpartum Depression
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression (PPD). SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. This drug was initially [...]
Brexanolone: Related to Allopregnanolone, Effective for the Treatment of Postpartum Depression
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression. Â SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. Â This drug was initially under [...]
![By Vera Kratochvil [Public domain], via Wikimedia Commons](https://womensmentalhealth.org/wp-content/uploads/2015/06/Mother_Kissing_Baby-320x202.jpg)
More Data on SAGE-547, A Novel Treatment for Severe Postpartum Depression
About a year ago, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression. Â SAGE-547 Â is a new drug, an allosteric modulator of GABAA receptors, which was initially [...]
SAGE-547: A Novel Treatment for Severe Postpartum Depression?
SAGE-547 (SAGE Therapeutics) is a new drug, an allosteric modulator of GABAA receptors, which is currently under investigation for the treatment of refractory seizure disorders. Â It turns out that SAGE-547 may also be useful for [...]